The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding and Adaptation

  • ID: 1408352
  • June 2010
  • Region: Global
  • 55 Pages
  • CBR Pharma Insights
1 of 3

After a hotly contested national debate, healthcare reform legislation was passed in the spring of 2010. The legislation contains many long-term benefits for the pharmaceutical industry, but the industry must continue to play an active role in legislation implementation to ensure those benefits are realized.

Through the new laws, there are both wins and losses for the pharmaceutical industry, such as changes effecting Medicare/Medicaid, health insurance coverage expansion & protection, taxation and patent protection. However, on balance most changes hold significant long-term potential for the industry.

While pharma played a very important role in promoting health reform during the debate over change, the work is not done. Many of the greatest potential benefits of the legislation – including extending healthcare coverage to 32 million more Americans – will come down the road. Thus, it is crucial for pharma to remain involved with the healthcare reform roll-out going forward.

Reasons to Purchase

- Analyze the possible impact that the new healthcare reform legislation could have on your company’s future growth potential

- Assess the role pharmaceutical companies need to play to best ensure that all potential benefits are actually realized

- Learn the pitfalls for the pharmaceutical industry to avoid as the new legislation is rolled-out

- Identify the opportunities for growth in the new reform environment

- Understand the ways the new healthcare reform bill can help change how healthcare is delivered in the United States

Note: Product cover images may vary from those shown
2 of 3

Executive Summary

- Background to the Patient Protection and Affordable Care Act of 2010
- Timeline for Reform

Wins and Losses for Pharma
- Costs for the Pharmaceutical Industry
- Taxation of “Cadillac” Plans
- Medicare and Medicaid
- - Medicare Part D
- - Medicaid Rebates
- - Rewarding and Punishing Outcomes
- Coverage Expansion
- - Marketplace Exchanges
- - Pre-existing Conditions
- - Early Retirement and Young Adults
- Coverage Protection
- - Ending Rescissions and Caps
- - Clinical Trial Participation
- Preventative Care and Accessibility
- Patent Protection for Biologics
- Biomedical Research Tax Credits
- Greater Transparency for Insurance Companies
- What Isn’t in the Act
- - CER Requirements
- - Drug Importation
- - Pay for Delay Ban
- - Extended Hospital Drug Discount

What Pharma Needs to Do Now
- Changing the Way the US Delivers Healthcare
- - Paying per Procedure to Paying per Outcome
- - Provider Shortfall
- - Shifting to Preventative Medicine
- Implementation at the State Level
- - Marketplace Exchanges
- Immediate vs. Longer-Term Impacts
- - Protections
- - Costs
- - Taxes and Coverage Expansion
- Fall Elections and Public Perceptions


Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown





Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.